Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 20/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 16/20 | 1.00 |
| ▸ | CASP3 | P42574 | 6/20 | 1.00 |
| ▸ | CASP7 | P55210 | 6/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 1.00 |
| ▸ | CDK2 | P24941 | 1/20 | 1.00 |
| ▸ | GSK3B | P49841 | 1/20 | 1.00 |
| ▸ | CDK7 | P50613 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16041025 | 1.00 | CDK9 (1.00) | CDK9CCNT1CASP3CASP7CDK1 | |
| SCHEMBL16041446 | 0.94 | CDK9 (1.00) | CDK9CCNT1CASP3CASP7CDK1 | |
| SCHEMBL16042808 | 0.92 | CCNT1 (1.00) | CDK9CCNT1CASP3CASP7CDK1 | |
| SCHEMBL16043010 | 0.88 | CCNT1 (1.00) | CDK9CCNT1CASP3CASP7CDK1 | |
| SCHEMBL16041780 | 0.88 | CCNT1 (1.00) | CDK9CCNT1CASP3CASP7CDK1 | |
| SCHEMBL16042567 | 0.88 | CDK9 (1.00) | CDK9CCNT1CASP3CASP7CDK1 | |
| SCHEMBL16041546 | 0.88 | CDK9 (1.00) | CDK9CCNT1CASP3CASP7CDK1 | |
| SCHEMBL16040358 | 0.87 | CDK9 (1.00) | CDK9CCNT1CASP3CASP7CDK1 | |
| SCHEMBL16040847 | 0.85 | CCNT1 (1.00) | CDK9CCNT1CASP3CASP7CDK1 | |
| SCHEMBL16042576 | 0.85 | CCNT1 (1.00) | CDK9CCNT1CASP3CASP7CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024054953-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |